We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Blue Trust Inc. grew its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 21.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

How Do Unusual Items Influence Profit? For anyone who wants to understand Biogen's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the shares following quarterly results. Though Biogen has ...